Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
06/20/2025 | PUT | $125.00 | 1,420 | +14 | +1.00% |
07/18/2025 | CALL | $130.00 | 75 | +10 | +15.38% |
01/16/2026 | CALL | $125.00 | 38 | +10 | +35.71% |
10/17/2025 | CALL | $120.00 | 11 | +3 | +37.50% |
12/19/2025 | CALL | $125.00 | 5 | +3 | +150.00% |
12/19/2025 | CALL | $120.00 | 69 | +2 | +2.99% |
01/16/2026 | PUT | $125.00 | 1,145 | 0 | |
01/16/2026 | PUT | $130.00 | 30 | 0 | |
01/16/2026 | PUT | $135.00 | 0 | 0 | |
01/16/2026 | PUT | $140.00 | 0 | 0 | |
01/16/2026 | PUT | $145.00 | 0 | 0 | |
07/18/2025 | PUT | $125.00 | 140 | -1 | -0.71% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Specialized-Health Care Fund | 3.97% | 2.38M | 141.75M |
Vanguard Total Stock Market Index Fund | 3.02% | 1.81M | 107.84M |
Price (T.Rowe) New Horizons Fund | 2.82% | 1.69M | 100.69M |
Vanguard Small-Cap Index Fund | 2.57% | 1.54M | 91.84M |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.42% | 1.45M | 86.35M |
iShares Russell 2000 ETF | 2.19% | 1.32M | 78.42M |
Fidelity Advisor Biotechnology Fund | 2.16% | 1.3M | 77.16M |
Fidelity Select Portfolios - Biotechnology | 2.09% | 1.25M | 74.74M |
Price (T.Rowe) Health Sciences Fund | 1.87% | 1.12M | 66.91M |
Fidelity Select Portfolios - Health Care | 1.67% | 1M | 59.58M |
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
06/06 03:37 pm
Benzinga
Read moreSanofi Expands Rare Immunology Portfolio With Blueprint Buyout
06/02 08:12 am
Benzinga
Read moreNUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
01/09 11:53 am
GlobeNewswire Inc.
Read moreExpert Ratings For Blueprint Medicines
06/28 09:00 am
Benzinga
Read moreAssessing Blueprint Medicines: Insights From 16 Financial Analysts
06/07 02:01 pm
Benzinga
Read moreUnveiling 18 Analyst Insights On Blueprint Medicines
05/14 12:00 pm
Benzinga
Read moreZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
05/07 06:40 am
Zacks Investment Research
Read morePetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
05/06 01:00 pm
Zacks Investment Research
Read more5 Biotech Stocks Worth Adding to Your Portfolio in 2024
05/06 09:50 am
Zacks Investment Research
Read moreBlueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
05/03 09:51 am
Zacks Investment Research
Read moreZoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
05/02 12:32 pm
Zacks Investment Research
Read moreBlueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
05/02 08:10 am
Zacks Investment Research
Read moreStrength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
05/01 01:04 pm
Zacks Investment Research
Read moreOrganon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
05/01 11:03 am
Zacks Investment Research
Read moreWhat's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
04/30 12:22 pm
Zacks Investment Research
Read moreWill Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
04/30 10:00 am
Zacks Investment Research
Read moreSustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
04/29 12:21 pm
Zacks Investment Research
Read moreFactors Setting the Tone for Ecolab's (ECL) Q1 Earnings
04/26 01:10 pm
Zacks Investment Research
Read moreThe Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
04/26 08:00 am
Benzinga
Read moreBlueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
04/25 10:01 am
Zacks Investment Research
Read moreDecoding 6 Analyst Evaluations For Blueprint Medicines
04/10 03:00 pm
Benzinga
Read moreCRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
03/22 11:30 am
Zacks Investment Research
Read moreWhy Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
03/21 11:30 am
Zacks Investment Research
Read moreModerna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
03/12 08:03 am
Zacks Investment Research
Read moreHere's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings
02/16 04:30 pm
Zacks Investment Research
Read moreBlueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines
02/16 06:47 am
Zacks Investment Research
Read moreReliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
02/15 11:23 am
Benzinga
Read moreBlueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
02/15 09:25 am
Zacks Investment Research
Read moreDrug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
02/14 11:12 am
Zacks Investment Research
Read moreApellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
02/13 11:00 am
Zacks Investment Research
Read moreCracking The Code: Understanding Analyst Reviews For Blueprint Medicines
02/13 11:00 am
Benzinga
Read moreSeeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
02/12 10:16 am
Zacks Investment Research
Read moreBlueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
02/08 11:00 am
Zacks Investment Research
Read moreVertex (VRTX) to Report Q4 Earnings: What's in the Cards?
02/02 11:47 am
Zacks Investment Research
Read moreGilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
02/02 09:28 am
Zacks Investment Research
Read moreWhat Makes Blueprint Medicines (BPMC) a New Buy Stock
01/16 01:00 pm
Zacks Investment Research
Read moreReasons to Add Blueprint (BPMC) Stock to Your Portfolio Now
01/16 12:51 pm
Zacks Investment Research
Read morePeeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
01/09 11:00 am
Benzinga
Read moreBiotech stocks set for a rebound in 2024, analysts say
12/23 07:50 am
MarketWatch
Read moreRaymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
12/22 01:00 pm
Benzinga
Read moreBlueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
12/13 01:56 pm
Zacks Investment Research
Read moreThe Latest Analyst Ratings for Blueprint Medicines
12/11 08:00 am
Benzinga
Read moreWhy Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
12/07 12:30 pm
Zacks Investment Research
Read moreWhy Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
12/06 12:30 pm
Zacks Investment Research
Read moreWhy Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?
12/01 12:32 pm
Zacks Investment Research
Read moreRepligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?
11/30 12:31 pm
Zacks Investment Research
Read moreWhy Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
11/29 12:30 pm
Zacks Investment Research
Read moreIs Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
11/16 10:40 am
Zacks Investment Research
Read moreHow Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16%
10/31 09:55 am
Zacks Investment Research
Read more